* Astrazeneca receives complete response letter from us fda
for sodium zirconium cyclosilicate (zs-9) for oral suspension
for treatment of hyperkalaemia
The post BRIEF-AstraZeneca receives complete response letter from U.S. FDA for sodium zirconium cyclosilicate appeared first on NASDAQ.